Orphan Diseases Open Opportunity for Pharma, Biotech Drug Developers
Orphan Diseases Attract Increasing Attention Across the Board As patents expire and generic competition increases, more drug companies are investing in the development of therapeutics for orphan diseases. Although the pool of patients for an orphan disease is small, the economic potential of an expensive biologic administered over the lifetime of a limited number of patients presents an attractive commercial opportunity that is a savvy alternative to the en [...]